Fluxergy Announces $30 Million to Expand Manufacturing Capacity of its One-Hour Diagnostic System

Fluxergy’s Co-Founder & President Tej Patel (left) and Investor & Co-Founder of Kingston Technologies, John Tu (right) with the Fluxergy Analyzer and Test Card.

 

IRVINE, CA, May 13, 2020 — Irvine, California-based Fluxergy, a diagnostic test company, is making a $30 million investment to rapidly expand its capability to scale production of the Fluxergy Analyzer diagnostic testing system in response to the COVID-19 pandemic.

The Fluxergy Analyzer system, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to accurately identify the SARS-CoV-2 virus in under one hour in bench lab validation studies conducted by the company, and with patient samples by physician-scientists at the University of California San Diego. Fluxergy also announced that it has started additional validation studies at other world-leading health systems and plans to continue making its innovative testing platform available as a Research Use Only (RUO) system for suitable partners during the current public health emergency.

The Fluxergy Analyzer System: single-use consumable Fluxergy Card, Fluxergy Analyzer, and its user interface Fluxergy Works

“We anticipate that our significant investment to step up our manufacturing capability will enable Fluxergy to deliver as many as one million tests per month by the end of 2020, and reflects our confidence in our technology as an important and innovative solution in expanding COVID-19 testing capability,” said Dr. Ali Tinazli, Chief Commercial Officer of Fluxergy.

Fluxergy recently filed a request for an Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) Center For Devices and Radiological Health, which, if granted, would permit medical sites with CLIA-certified high complexity laboratories to begin using the company’s high-speed test system as a COVID-19 diagnostic tool in accordance with the scope of FDA’s authorization.

About Fluxergy

Fluxergy, launched in 2013 with funding support of principal investor and Kingston Technology’s co-founder John Tu, seeks to provide a portable, easy to use sample-to-answer POC platform that enables clinicians to cost-effectively conduct a wide range of multiplex and multimodal in vitro diagnostic tests (different types of tests all at once, up to 30 targets). Core elements: single-use consumable Fluxergy Card, Fluxergy Analyzer, and its user interface Fluxergy Works. The Fluxergy Cards (lab-on-chip) are designed to be very cost-effective and scalable, using proprietary printed circuit board (PCB) manufacturing and microfluidics technologies.

Please visit fluxergy.com for more information.

CONTACT: Dr. Ali Tinazli, atinazli@fluxergy.com +1 310-467-1112

Share:

Share on linkedin
LinkedIn
Share on twitter
Twitter
Share on email
Email
Share on facebook
Facebook
Share on reddit
Reddit

Fluxergy Corporate Campus

US Headquarters
30 Fairbanks, Irvine, CA 92618
+1(949) 305-4201
info@fluxergy.com

R&D Center
13766 Alton Pkwy, Irvine, CA 92618

Manufacturing Center
15 Musick, Irvine, CA 92618

Fluxergy Europe GmbH i.G.
Eichenstr. 4  63667 Nidda, Germany
+49 6043 403518

*Only Fluxergy Test Kit COVID-19 has been approved for CE-IVD and is available for any markets that accept CE marking as the valid regulatory approval.

All other products or any other markets are For Research Use Only (RUO) and are not for use in diagnostic procedures.

*This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Fluxergy takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.

*Although forward-looking statements contained in this website regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Copyright 2021 Fluxergy